This drug is being developed for the treatment of paroxysmal supraventricular tachycardia (PSVT), a condition characterized by sudden, rapid heartbeats. While the CRL raises no concerns about the ...

PSVT is a type of arrhythmia causing rapid heartbeat in areas of the heart above the ventricles, and is caused by abnormal electrical pathways in the heart. It can cause dizziness, palpitations ...

“We are deeply disappointed by the CRL but remain committed to the potential of CARDAMYST as a novel treatment option that can help patients with PSVT. Our team is evaluating the feedback ...

Atrioventricular nodal reentrant tachycardia is the most common form of paroxysmal supraventricular tachycardia, or PSVT, in adults. AVNRT occurs when a reentrant circuit is present within the AV ...

The nasal spray is under development to treat episodes of abnormal heart rhythm associated with Paroxysmal supraventricular tachycardia (PSVT ... at ‘extremely high’ levels over the past ...

Milestone Pharmaceuticals faces an FDA setback for its PSVT nasal spray. The company coordinates with regulatory authorities to resolve CRL issues. TD Cowen downgraded Milestone Pharmaceuticals ...

“This presentation highlights the potential ability of etripamil to successfully convert multiple episodes of Paroxysmal Supraventricular Tachycardia (PSVT) to restore normal sinus rhyth ...

"We are deeply disappointed by the CRL but remain committed to the potential of CARDAMYST as a novel treatment option that can help patients with PSVT. Our team is evaluating the feedback provided and ...

"We are deeply disappointed by the CRL but remain committed to the potential of CARDAMYST as a novel treatment option that can help patients with PSVT. Our team is evaluating the feedback provided ...